Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial
(2022)
Journal Article
Mackenzie, I. S., Hawkey, C. J., Ford, I., Greenlaw, N., Pigazzani, F., Rogers, A., …MacDonald, T. M. (2022). Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10359), 1195-1205. https://doi.org/10.1016/S0140-6736%2822%2901657-9
Background: Allopurinol is a urate-lowering therapy used to treat patients with gout. Previous studies have shown that allopurinol has positive effects on several cardiovascular parameters. The ALL-HEART study aimed to determine whether allopurinol t... Read More about Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.